Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
Author:
Funder
Institut National du Cancer
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Link
http://link.springer.com/content/pdf/10.1007/s11136-019-02367-7.pdf
Reference58 articles.
1. Efficace, F., Fayers, P., Pusic, A., Cemal, Y., Yanagawa, J., Jacobs, M., et al. (2015). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer,121(18), 3335–3342. https://doi.org/10.1002/cncr.29489.
2. Secord, A. A., Coleman, R. L., Havrilesky, L. J., Abernethy, A. P., Samsa, G. P., & Cella, D. (2015). Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews. Clinical Oncology,12(6), 358–370. https://doi.org/10.1038/nrclinonc.2015.29.
3. Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology,34(16), 1953–1956. https://doi.org/10.1200/JCO.2014.56.7974.
4. Cnaan, A., Laird, N. M., & Slasor, P. (1997). Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine,16(20), 2349–2380.
5. Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials. London: Chapman and Hall/CRC.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials;Journal of Clinical Epidemiology;2023-10
2. Can time to deterioration in patient-reported outcomes be a surrogate for overall survival?;JNCI: Journal of the National Cancer Institute;2023-09-02
3. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis;JNCI: Journal of the National Cancer Institute;2023-08-04
4. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial;GYNECOL ONCOL;2023
5. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial;Gynecologic Oncology;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3